JP2003516930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516930A5 JP2003516930A5 JP2001516518A JP2001516518A JP2003516930A5 JP 2003516930 A5 JP2003516930 A5 JP 2003516930A5 JP 2001516518 A JP2001516518 A JP 2001516518A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2003516930 A5 JP2003516930 A5 JP 2003516930A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- epha2
- antibody
- metastatic
- cell density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 22
- 102000051096 EphA2 Receptor Human genes 0.000 description 10
- 108010055196 EphA2 Receptor Proteins 0.000 description 10
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14925899P | 1999-08-17 | 1999-08-17 | |
| US60/149,258 | 1999-08-17 | ||
| PCT/US2000/022670 WO2001012172A1 (en) | 1999-08-17 | 2000-08-17 | Treatment of metastatic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007211840A Division JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516930A JP2003516930A (ja) | 2003-05-20 |
| JP2003516930A5 true JP2003516930A5 (https=) | 2008-06-05 |
Family
ID=22529456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516518A Pending JP2003516930A (ja) | 1999-08-17 | 2000-08-17 | 転移性疾患の治療 |
| JP2007211840A Pending JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007211840A Pending JP2007306938A (ja) | 1999-08-17 | 2007-08-15 | 転移性疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2289940A3 (https=) |
| JP (2) | JP2003516930A (https=) |
| AT (1) | ATE324877T1 (https=) |
| AU (1) | AU6784400A (https=) |
| CA (1) | CA2380888A1 (https=) |
| DE (1) | DE60027768T2 (https=) |
| DK (1) | DK1242060T3 (https=) |
| ES (1) | ES2261230T3 (https=) |
| PT (1) | PT1242060E (https=) |
| WO (1) | WO2001012172A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| CN1441676B (zh) | 2000-03-31 | 2012-08-22 | 普渡研究基金会 | 用配体-免疫原缀合物治疗的方法 |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| NZ537458A (en) * | 2001-01-23 | 2007-02-23 | Primagen Holding B | Means and methods for treatment evaluation |
| EP1298221A1 (en) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Means and methods for treatment evaluation |
| EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
| EP2168598A1 (en) * | 2001-09-28 | 2010-03-31 | Purdue Research Foundation | Method of Treatment Using Ligand-Immunogen Conjugates |
| WO2003070883A2 (en) * | 2002-02-15 | 2003-08-28 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| ATE525398T1 (de) * | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
| JP4585968B2 (ja) * | 2002-05-10 | 2010-11-24 | パーデュー・リサーチ・ファウンデーション | ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法 |
| US7662770B2 (en) | 2002-05-23 | 2010-02-16 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
| AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
| WO2004091375A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| CA2525929A1 (en) | 2003-05-13 | 2004-11-25 | Chiron Corporation | Methods of modulating metastasis and skeletal related events resulting from metastases |
| WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| EP1689346A4 (en) * | 2003-11-20 | 2007-11-21 | Medimmune Inc | EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF |
| CN1989250B (zh) | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| CN101155830B (zh) | 2005-02-04 | 2014-06-18 | 雷文生物技术公司 | 结合epha2的抗体及其使用方法 |
| US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
| MX2009000709A (es) * | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| CA2663295C (en) | 2006-09-12 | 2020-03-10 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| ES2746960T3 (es) | 2006-09-12 | 2020-03-09 | Alphavax Inc | Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos |
| DK2099485T3 (en) | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alphavirus and alphavirus replica particle formulations and associated methods |
| BRPI0816094A2 (pt) * | 2007-08-30 | 2015-03-03 | Daiichi Sankyo Co Ltd | Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo. |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| JP6729917B2 (ja) * | 2016-08-19 | 2020-07-29 | 国立大学法人 東京大学 | ＥｐｈＡ２ Ｎ末端フラグメント抗体 |
| US20210268098A1 (en) | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69228300T2 (de) | 1991-08-22 | 1999-09-23 | Becton Dickinson And Co., Franklin Lakes | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
| CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
-
2000
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 EP EP10010861A patent/EP2289940A3/en not_active Withdrawn
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
- 2000-08-17 EP EP00955687A patent/EP1242060B1/en not_active Revoked
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en not_active Ceased
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516930A5 (https=) | ||
| Moro et al. | CEA, CYFRA21-1 and SCC in non-small cell lung cancer | |
| Kind et al. | Seismic images of the biggest crash on Earth | |
| JP2006502416A5 (https=) | ||
| DE69503903D1 (de) | Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung | |
| Tateyama et al. | Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma | |
| JP2004528574A5 (https=) | ||
| MXPA02012424A (es) | Ensayo de combinacion de antigenos/anticuerpos para el virus de hepatitis c. | |
| RU2005131842A (ru) | Моноклональное антитело и продуцирующая его гибридома | |
| WO2002082076A3 (en) | Renal cell carcinoma tumor markers | |
| CA2436595A1 (en) | Chronic lymphocytic leukemia cell line and its use for producing an antibody | |
| ATE464374T1 (de) | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen | |
| WO2001012840A3 (en) | Anti-epha2 antibodies as a cancer diagnostic | |
| JP2005516374A5 (https=) | ||
| Yan et al. | Measurement of denitrification in the Changjiang River | |
| Golubić et al. | Schizothrix gebeleinii sp. nova builds subtidal stromatolites, Lee Stocking Island, Bahamas | |
| DE69430313D1 (de) | Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen | |
| DK1135170T3 (da) | Radiokonjugation af internaliserende antistoffer | |
| JPS5332114A (en) | Quantitative determination of antigen and antibody | |
| AU636964B2 (en) | Immunological detection of metolachlor | |
| EP0323802A3 (en) | Monoclonal antibodies against, and cell surface antigen of, lung carcinoma | |
| Buchner et al. | Expression of plakoglobin in renal cell carcinoma | |
| Garzetti et al. | Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index | |
| JP2002000270A5 (https=) | ||
| HANZAWA | A new type of Lepidocyclina with a multilocular nucleoconch from the Taito Mountains, Taiwan (Formosa) |